155 related articles for article (PubMed ID: 32284297)
1. Intensive Induction Therapy Compared With CHOP for Hepatosplenic T-cell Lymphoma.
Klebaner D; Koura D; Tzachanis D; Ball ED; Horwitz S; Goodman AM
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):431-437.e2. PubMed ID: 32284297
[TBL] [Abstract][Full Text] [Related]
2. Clinical features and treatment outcomes of 14 patients with hepatosplenic γ δ T-cell lymphoma.
Wang Q; Jiang Y; Zhu Q; Duan Y; Chen X; Xu T; Jin Z; Li C; Wu D; Huang H
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3441-3445. PubMed ID: 33856526
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
5. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.
Lefrère F; Delmer A; Suzan F; Levy V; Belanger C; Djabarri M; Arnulf B; Damaj G; Maillard N; Ribrag V; Janvier M; Sebban C; Casasnovas RO; Bouabdallah R; Dreyfus F; Verkarre V; Delabesse E; Valensi F; McIntyre E; Brousse N; Varet B; Hermine O
Leukemia; 2002 Apr; 16(4):587-93. PubMed ID: 11960337
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
Qin Y; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang JL; Yang S; Zhang CG; Dong M; Zhou LQ; Wang JW; Feng FY; Sun Y
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):469-73. PubMed ID: 19950562
[TBL] [Abstract][Full Text] [Related]
7. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
Herrmann K; Buck AK; Schuster T; Junger A; Wieder HA; Graf N; Ringshausen I; Rudelius M; Wester HJ; Schwaiger M; Keller U; Dechow T
J Nucl Med; 2011 May; 52(5):690-6. PubMed ID: 21498532
[TBL] [Abstract][Full Text] [Related]
9. The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review.
Ashaye AO; Burnett H; Abogunrin S; Panchmatia H; Ovcinnikova O; Dalal M
Future Oncol; 2022 Feb; 18(4):519-535. PubMed ID: 34851173
[TBL] [Abstract][Full Text] [Related]
10. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
[No Abstract] [Full Text] [Related]
11. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience.
Voss MH; Lunning MA; Maragulia JC; Papadopoulos EB; Goldberg J; Zelenetz AD; Horwitz SM
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):8-14. PubMed ID: 23107915
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry.
Kida S; Fuji S; Morishima T; Nakata K; Miyashiro I; Ishikawa J
Int J Hematol; 2021 Aug; 114(2):246-251. PubMed ID: 33864237
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
[TBL] [Abstract][Full Text] [Related]
14. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Prayoonwiwat W; Numbenjapon T; Assawametha N; O'Charoen R; Swasdikul D
Clin Lymphoma; 2000 Dec; 1(3):219-25. PubMed ID: 11707834
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
16. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
[TBL] [Abstract][Full Text] [Related]
17. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
18. High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma.
Hyun SY; Cheong JW; Kim SJ; Min YH; Yang DH; Ahn JS; Lee WS; Ryoo HM; Do YR; Lee HS; Lee JH; Oh SY; Suh C; Yhim HY; Kim JS
Biol Blood Marrow Transplant; 2014 Jan; 20(1):73-9. PubMed ID: 24141009
[TBL] [Abstract][Full Text] [Related]
19. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients.
Janikova A; Chloupkova R; Campr V; Klener P; Hamouzova J; Belada D; Prochazka V; Pytlik R; Pirnos J; Duras J; Mocikova H; Bortlicek Z; Kopalova N; Mayer J; Trneny M
Ann Hematol; 2019 Aug; 98(8):1961-1972. PubMed ID: 31065733
[TBL] [Abstract][Full Text] [Related]
20. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]